Skip to content

For healthcare providers

For clinicians whose patients bring a GeneMatrix report: what the genotyping covers, the evidence behind each result, its limits, and how to reach our lab.

By the GeneMatrix editorial teamUpdated 2 min read

A doctor’s office desk by a window: a folded letter under a pair of reading glasses, a pen, a mug and a stethoscope.

In short

This page is for clinicians whose patients bring a GeneMatrix report. Our genetic tests are genotyping panels: each checks selected, known variants rather than whole genes, so a result with nothing found can’t rule out a variant the panel doesn’t read. Below: what each report covers, where its guidance comes from, its limits, and how to reach our laboratory.

On this page
  1. Who runs the laboratory?
  2. What does a GenePGx report cover?
  3. How should a GeneCancer result be read?
  4. What are the wellness reports?
  5. Can I see a sample report?
  6. How long do results take, and how do they reach the patient?
  7. How do I contact the laboratory?

Who runs the laboratory?

Our genetic tests are genotyped in our own CLIA-certified laboratory in Chicago (New York orders excepted), at Fulton Labs, 1375 W Fulton St, Suite 545, Chicago, IL 60607. The laboratory’s CLIA certificate is 14D2276402, and its organizational NPI is 1225729312.

Our genetic tests are laboratory-developed tests performed in our own CLIA-certified laboratory. New York is the exception: orders shipped there are completed through a physician order or a reference laboratory permitted in New York. Our genetic tests have not been cleared or approved by the FDA. Results describe inherited traits and risks and are meant to inform decisions you make with your clinician. They are not a diagnosis.

The laboratory is directed by a board-certified CLIA high-complexity laboratory director, and results are released under the director’s responsibility. Our lab page shows the certificate and names the director, with his credentials.

What does a GenePGx report cover?

GenePGx is our pharmacogenomic panel. Its page lists the 15 genes and describes the panel to patients in these words:

  • Scope. Checks selected known variants in 15 genes, plus CYP2D6 copy number, by genotyping.
  • Guidelines. It tests genes named in CPIC prescribing guidelines for 56 medicines (checked September 29, 2026).[1]
  • CYP2D6 copies. It counts copies of the CYP2D6 gene, so a missing copy or extra copies show in your result.
  • DPYD. It checks DPYD, a gene named in CPIC guidance for some chemotherapy medicines.
  • HLA. Checks four specific HLA types linked to serious medicine reactions. It does not identify your full HLA type. The four: HLA-A*31:01, HLA-B*15:02, HLA-B*57:01 and HLA-B*58:01.
  • Limits. It checks a set list of known variants in these genes and counts copies of the CYP2D6 gene. It does not read whole genes, so it can miss rare or new variants, and a result with no variant found does not rule out a change in how you process a medicine.
  • Not tested. GenePGx does not test G6PD, ABCG2, IFNL3, NAT2, RYR1, CACNA1S, MT-RNR1, CFTR, OPRM1, COMT, SLC6A4, HTR2A or MTHFR. Of UGT1A1’s variants, it does not test *28, *37 or *80.
  • How to use a result. It is a starting point for your own review against current guidance, not a prescribing instruction.

Pharmacogenomic results describe how your body is likely to process certain medicines. They do not tell you whether a medicine will work for you, and they are not dosing instructions. Never start, stop or change a medication because of a genetic result. Bring it to the prescriber who manages your medicines.

How should a GeneCancer result be read?

GeneCancer is our at-home test for inherited cancer risk. Scope: Checks selected variants across 108 genes, including BRCA1 and BRCA2, by genotyping. It looks at chosen positions, not whole genes, so it can miss rare variants that a clinical test reading each gene in full would find.[2] It does not check RAD51C, RAD51D or HOXB13.

A result with no variant found can’t rule out inherited cancer risk.

  • A variant reported. Confirm it with clinical testing before any decision; variants reported by direct-to-consumer tests have not always held up on clinical confirmation.[3]
  • No variant found. Reassuring only for the variants the panel checks. It doesn’t rule out inherited cancer risk, and the patient’s personal and family history still guides screening.
  • A personal or family history of cancer. Clinical testing that reads whole genes is the place to start, whatever this result says.

If you or a close relative has had cancer, ask your doctor about full-gene clinical testing.

What are the wellness reports?

GeneCore, GeneDiet, GeneSport, GeneHealth and GeneResilience report genetic traits studied in diet, fitness and everyday wellbeing. They describe associations seen in groups of people, not a diagnosis or a treatment plan.

For general wellness and information, not diagnosis.

Our nutrition, supplement, athletic and wellbeing reports are for general wellness and information. The evidence behind these associations is less established than for our clinical panels, and these reports are not intended to diagnose, treat, cure or prevent any disease.

Can I see a sample report?

Yes. The sample report shows how our reports are laid out, with made-up results, so you can see where the summary, each result and its limits sit before a patient’s report reaches you.

How long do results take, and how do they reach the patient?

What we tell patients: Results are usually ready 5 to 7 business days after the lab receives your activated sample (10 to 14 business days during holiday weeks). When your results are ready we email you (the email never names your test) with the lab’s secure link to your report, which asks for the tested person’s details before it opens. The report goes to the patient, who decides whom to share it with.

How do I contact the laboratory?

For questions about a report, our methods or the laboratory, call +1-847-302-9668 or email info@genematrix.io. Contact lists the other ways to reach us.

Sources

  1. [1]Genes and drugs: CPIC levels for each gene and drug pair. Clinical Pharmacogenetics Implementation Consortium (CPIC). Accessed .
  2. [2]Use of SNP chips to detect rare pathogenic variants: retrospective, population based diagnostic evaluation. BMJ, 2021. Accessed .
  3. [3]False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care. Genetics in Medicine, 2018. Accessed .

How we write and source these pieces: our editorial policy.

Related reading

Please read

LabOur genetic tests are laboratory-developed tests performed in our own CLIA-certified laboratory. New York is the exception: orders shipped there are completed through a physician order or a reference laboratory permitted in New York. Our genetic tests have not been cleared or approved by the FDA. Results describe inherited traits and risks and are meant to inform decisions you make with your clinician. They are not a diagnosis.

PGxPharmacogenomic results describe how your body is likely to process certain medicines. They do not tell you whether a medicine will work for you, and they are not dosing instructions. Never start, stop or change a medication because of a genetic result. Bring it to the prescriber who manages your medicines.

NoteA result with no variant found can’t rule out inherited cancer risk.

NoteIf you or a close relative has had cancer, ask your doctor about full-gene clinical testing.

NoteFor general wellness and information, not diagnosis.

WellnessOur nutrition, supplement, athletic and wellbeing reports are for general wellness and information. The evidence behind these associations is less established than for our clinical panels, and these reports are not intended to diagnose, treat, cure or prevent any disease.